Glucagon-like peptide-1 analogues in monogenic syndromic obesity: real-world data from a large cohort of Alström syndrome patients.
Ali, Sadaf Baig, Shanat Wanninayake, Subadra da Silva Xavier, Gabriela Dawson, Charlotte Paisey, Richard Geberhiwot, Tarekegn
Ali, Sadaf
Baig, Shanat
Wanninayake, Subadra
da Silva Xavier, Gabriela
Dawson, Charlotte
Paisey, Richard
Geberhiwot, Tarekegn
Abstract
Aim: To examine the real-world efficacy of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in monogenic obesity in patients with Alström syndrome (ALMS).
Methods: We screened 72 UK adult patients with ALMS and offered treatment to 34 patients meeting one of the following criteria: body mass index of 25 kg/m2 or higher, insulin resistance, suboptimal glycaemic control on antihyperglycaemic medications or non-alcoholic fatty liver disease.
Results: In total, 30 patients, with a mean age of 31 ± 11 years and a male to-female ratio of 2:1, completed 6 months of treatment with GLP-1 RAs either in the form of semaglutide or exenatide. On average, treatment with GLP-1 RAs reduced body weight by 5.4 ± 1.7 (95% confidence interval [CI] 3.6-7) kg and HbA1c by 12 ± 3.3 (95% CI 8.7-15.3) mmol/mol, equating to 6% weight loss (P < .01) and 1.1% absolute reduction in HbA1c (P < .01). Significant improvements were also observed in serum total cholesterol, triglycerides, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol and alanine aminotransferase. The improvement of metabolic variables in our cohort of monogenic syndromic obesity was comparable with data for polygenic obesity, irrespective of weight loss.
Conclusions: Data from our centre highlight the non-inferiority of GLP-1 RAs in monogenic syndromic obesity to the available GLP-1 RA-use data in polygenic obesity, therefore, these agents can be considered as a treatment option in patients with ALMS, as well as other forms of monogenic obesity.
MIDER Authors
Citations
Altmetric:
Date
2023-12-27
Type
Article
Collections
Citation
Ali S, Baig S, Wanninayake S, da Silva Xavier G, Dawson C, Paisey R, Geberhiwot T. Glucagon-like peptide-1 analogues in monogenic syndromic obesity: Real-world data from a large cohort of Alström syndrome patients. Diabetes Obes Metab. 2024 Mar;26(3):989-996. doi: 10.1111/dom.15398. Epub 2023 Dec 27.
Journal / Source Title
Diabetes, Obesity and Metabolism
DOI
10.1111/dom.15398
PMID
38151964
Publisher
Wiley
Publisher’s URL
https://pubmed.ncbi.nlm.nih.gov/38151964/